Press release - May 17th, 2011
Cerbomed at the INS 10th World Congress
ERLANGEN, Germany, 17.05.2011 – The medical device company cerbomed GmbH is proud to present NEMOS, the world’s first medical device for transcutaneous Vagus Nerve Stimulation (t-VNS), at the 10. World Congress of the International Neuromodulation Society in London.
Please save May 25th and use the chance to get additional information about t-VNS at the INS Class-room Session at 11.35 a.m. and at two poster presentations.
NEMOS is intended for people suffering from various difficult to treat neurological and psychiatric diseases. The current lead indications are drug-resistant epilepsies. Further indications such as chronic pain, tinnitus and schizophrenia are currently being evaluated in clinical studies.
Cerbomed’s t-VNS therapy uses the fact that a branch of the vagus nerve is located directly under the skin in areas of the outer ear and that nerves can be stimulated through the skin (transcuta-neously) with electrical impulses. NEMOS consists of a stimulation unit and an ear electrode which the patient wears in the ear like an earphone for 3 to 5 hours per day.
Cerbomed expects NEMOS to offer a highly attractive and cost-effective alternative to current and emerging VNS treatments, other neurostimulation methods, surgery or pharmacologic therapies. These therapeutic alternatives are connected either with higher risks or have undesirable side ef-fects. Such alternatives are also often considerably less effective and more expensive.
Cerbomed is a privately held medical device company based in Erlangen, Germany, aiming to be-come the leader for the development of non-invasive Vagus Nerve Stimulation (VNS) therapies. The company was founded in 2005 to develop and commercialize its proprietary, transcutaneous Vagus Nerve Stimulation (t-VNS) technology and devices for therapeutic uses. NEMOS products comprise the world’s first non-invasive VNS device enabling specific electrical brain stimulation. The company has received a CE-mark for NEMOS in Europe.